يعرض 1 - 3 نتائج من 3 نتيجة بحث عن '"Jung, SY"', وقت الاستعلام: 1.55s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.

    المؤلفون: Jeong JH, Jung SY, Park IH, Lee KS, Kang HS, Kim SW, Kwon Y, Kim EA, Ko KL, Nam BH, Lee S, Ro J

    المصدر: Investigational New Drugs; Feb2012, Vol. 30 Issue 1, p408-416, 9p

    Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.

    المؤلفون: Jung SY; Department of Pharmacy, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.; Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea., Hwang S; MedPacto, Inc., Seoul, Republic of Korea., Clarke JM; Duke University Medical Center, Durham, NC, USA., Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN, USA., Keedy VL; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA., Lee H; National OncoVenture, National Cancer Center, Goyang, Republic of Korea., Park N; National OncoVenture, National Cancer Center, Goyang, Republic of Korea., Kim SJ; MedPacto, Inc., Seoul, Republic of Korea., Lee JI; Department of Pharmacy, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea. jangik.lee@snu.ac.kr.; Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea. jangik.lee@snu.ac.kr.

    المصدر: Investigational new drugs [Invest New Drugs] 2020 Jun; Vol. 38 (3), pp. 812-820. Date of Electronic Publication: 2019 Jul 13.

    نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

    بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

    مواضيع طبية MeSH: Aniline Compounds/*pharmacokinetics , Aniline Compounds/*therapeutic use , Neoplasms/*drug therapy , Receptor, Transforming Growth Factor-beta Type I/*antagonists & inhibitors , Triazoles/*pharmacokinetics , Triazoles/*therapeutic use, Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Area Under Curve ; Drug Administration Schedule ; Female ; Half-Life ; Humans ; Male ; Middle Aged ; Neoplasms/metabolism

    Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.

    المؤلفون: Park IH; Center for Breast Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 410-769, Korea., Lee KS, Kang HS, Kim SW, Lee S, Jung SY, Kwon Y, Shin KH, Ko K, Nam BH, Ro J

    المصدر: Investigational new drugs [Invest New Drugs] 2012 Oct; Vol. 30 (5), pp. 1972-7. Date of Electronic Publication: 2011 Oct 18.

    نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

    بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

    مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*adverse effects , Breast Neoplasms/*drug therapy , Receptor, ErbB-2/*biosynthesis, Adult ; Aged ; Breast Neoplasms/enzymology ; Breast Neoplasms/genetics ; Breast Neoplasms/surgery ; Cohort Studies ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Humans ; Lapatinib ; Maximum Tolerated Dose ; Middle Aged ; Neoadjuvant Therapy/methods ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Quinazolines/administration & dosage ; Quinazolines/adverse effects ; Receptor, ErbB-2/antagonists & inhibitors ; Gemcitabine

    Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء